Literature DB >> 10821971

Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains.

I Kurane1, T Takasaki.   

Abstract

Mouse brain-derived, inactivated Japanese encephalitis (JE) vaccine has been internationally used for many years. It is believed that this vaccine made a great contribution to the reduction of JE patients in several countries. Mouse brain-derived, Beijing-1 and Nakayama JE vaccines induce high levels of neutralizing antibodies. High levels of induced antibodies are maintained at least for 3-4 yr. The induced antibodies are cross-reactive to heterologous strains; however, the neutralizing antibody titers against heterologous strains are usually lower than those against homologous strains. Considering that both Nakayama and Beijing-1 JE vaccines showed high levels of protective efficacy in Taiwan and Thailand where strains other than Nakayama and Beijing-1 were circulating, we conclude that the current inactivated JE vaccine can induce high levels of protective immunity against heterologous JE virus strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821971     DOI: 10.1016/s0264-410x(00)00041-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.

Authors:  Shigefumi Okamoto; Hironori Yoshii; Masaaki Matsuura; Asato Kojima; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Michiaki Takahashi; Koichi Yamanishi; Yasuko Mori
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.

Authors:  Peter E Nasveld; Andrew Ebringer; Nathan Elmes; Sonya Bennett; Sutee Yoksan; John Aaskov; Karen McCarthy; Niranjan Kanesa-thasan; Claude Meric; Mark Reid
Journal:  Hum Vaccin       Date:  2010-12-01

Review 3.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

Review 4.  Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.

Authors:  Theodore C Pierson; Daved H Fremont; Richard J Kuhn; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

5.  Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; Christopher T Hanson; Stephen S Whitehead
Journal:  Vaccine       Date:  2014-03-31       Impact factor: 3.641

6.  A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.

Authors:  Elina O Erra; Helena Hervius Askling; Lars Rombo; Jukka Riutta; Sirkka Vene; Sutee Yoksan; Lars Lindquist; Sari H Pakkanen; Eili Huhtamo; Olli Vapalahti; Anu Kantele
Journal:  Clin Infect Dis       Date:  2012-06-13       Impact factor: 9.079

Review 7.  Arboviral encephalitides: transmission, emergence, and pathogenesis.

Authors:  Bradley S Hollidge; Francisco González-Scarano; Samantha S Soldan
Journal:  J Neuroimmune Pharmacol       Date:  2010-07-22       Impact factor: 7.285

Review 8.  The present and future of veterinary vaccines for Japanese encephalitis in Korea.

Authors:  Jin-Ju Nah; Dong-Kun Yang; Ha-Hyun Kim; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

9.  Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.

Authors:  Matthew Bonaparte; Bashir Dweik; Emmanuel Feroldi; Claude Meric; Alain Bouckenooghe; Stephen Hildreth; Branda Hu; Sutee Yoksan; Mark Boaz
Journal:  BMC Infect Dis       Date:  2014-03-21       Impact factor: 3.090

10.  Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes.

Authors:  Elina O Erra; Helena Hervius Askling; Sutee Yoksan; Lars Rombo; Jukka Riutta; Sirkka Vene; Lars Lindquist; Olli Vapalahti; Anu Kantele
Journal:  Clin Infect Dis       Date:  2012-10-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.